华润双鹤：盐酸右哌甲酯缓释胶囊新进2025年国家医保目录

Core Viewpoint - China Resources Double Crane (华润双鹤) announced that its subsidiary, Henan Zhongshuai Pharmaceutical Co., Ltd., has successfully negotiated to include its product, methylphenidate hydrochloride sustained-release capsules, in the National Basic Medical Insurance, Maternity Insurance, and Work Injury Insurance Drug Catalog for 2025, with the agreement stipulating that the negotiated drug will be reimbursed under Category B [1] Group 1 - The product methylphenidate hydrochloride sustained-release capsules has been included in the National Basic Medical Insurance Drug Catalog [1] - The inclusion is a result of negotiations with the National Healthcare Security Administration and the Ministry of Human Resources and Social Security [1] - The agreement specifies that the drug will be reimbursed under Category B during the agreement period [1]